Acadian Asset Management LLC decreased its stake in MEI Pharma, Inc. (NASDAQ:MEIP – Free Report) by 29.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 150,150 shares of the company’s stock after selling 61,583 shares during the period. Acadian Asset Management LLC owned 2.25% of MEI Pharma worth $435,000 at the end of the most recent quarter.
Separately, National Bank of Canada FI grew its stake in MEI Pharma by 43.5% in the second quarter. National Bank of Canada FI now owns 33,000 shares of the company’s stock valued at $94,000 after purchasing an additional 10,000 shares in the last quarter. 52.38% of the stock is currently owned by hedge funds and other institutional investors.
MEI Pharma Stock Up 1.3 %
Shares of MEI Pharma stock opened at $3.04 on Thursday. The stock has a market capitalization of $20.26 million, a price-to-earnings ratio of 0.78 and a beta of 0.86. MEI Pharma, Inc. has a twelve month low of $2.73 and a twelve month high of $7.87. The company has a 50-day simple moving average of $3.20 and a two-hundred day simple moving average of $3.25.
Analysts Set New Price Targets
Read Our Latest Research Report on MEI Pharma
About MEI Pharma
MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.
See Also
- Five stocks we like better than MEI Pharma
- Overbought Stocks Explained: Should You Trade Them?
- How Much Can You Make in Stocks in One Month?
- Differences Between Momentum Investing and Long Term Investing
- This Is the Top Large-Cap Stock Insiders Are Buying
- Technology Stocks Explained: Here’s What to Know About Tech
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Want to see what other hedge funds are holding MEIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEI Pharma, Inc. (NASDAQ:MEIP – Free Report).
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.